Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
40 Items
Title  Creator  Group name  Publishing year 
Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features Boissière-Michot et al. EquipeCTCS 2024
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer Massa et al. EquipeCTCS 2024-12-01
First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study Bardol et al. EquipeCTCS 2024-01
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer Desroys du Roure et al. EquipePM 2024-01-30
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial Huober et al. EquipeELC 2023-08-10
Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study François-Martin et al. EquipeELC 2023-02-13
Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study Fabbro et al. EquipePC 2023-01
Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer David et al. EquipePM 2023-11-29
Unusual Focal Lung Uptake without CT Abnormality on a Bone Scan: What Might It Mean? Eberlé et al. EquipeJPP 2022-04-08
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity Alcaraz et al. EquipeELC 2022-11-08
Real-world evidence of the management and prognosis of young women (?40?years) with de novo metastatic breast cancer Mallet et al. EquipeELC 2022
Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects Leenhardt et al. EquipeCTCS 2022-04-11
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study Dalenc et al. EquipeELC 2022-03
Emotional processes in partners' quality of life at various stages of breast cancer pathway: a longitudinal study Baudry et al. EquipeELC 2022-11-24
Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer Boissière-Michot et al. EquipeELC 2022
Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes Carausu et al. EquipeELC 2022-12-01
Adjustment of young women with breast cancer after chemotherapy: A mediation model of emotional competence via emotional distress Baudry et al. EquipeELC 2022-01-05
Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers Jacot et al. EquipeELC 2021-12-01
Clinicopathological Correlates of ?? T Cell Infiltration in Triple-Negative Breast Cancer Boissière-Michot et al. EquipeCTCS 2021-02-12
Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer Viala et al. EquipeCTCS 2021-07-15
A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment Alcaraz et al. EquipeCTCS 2021
Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review Corbeau et al. EquipeCTCS 2020-04-13
Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14) Penault-Llorca et al. EquipeELC 2020-02
Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival Mansouri et al. EquipeCTCS 2020-05-15
Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer Jacot et al. EquipeELC 2020-08-01
12>>>
40 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés